Bitcoin Jumps Above $30,000; Internet Computer Emerges As Top Gainer

Bitcoin (CRYPTO: BTC) moved higher, with the cryptocurrency prices trading above the key $30,000 level on Tuesday. Ethereum (CRYPTO: ETH) also moved higher, surging past the key $2,100 mark this morning.

Bitcoin (CRYPTO: BTC) moved higher, with the cryptocurrency prices trading above the key $30,000 level on Tuesday.

Ethereum (CRYPTO: ETH) also moved higher, surging past the key $2,100 mark this morning.

Housing starts in the US fell 0.8% month-over-month to an annualized rate of 1.42 million in March, while building permits dipped 8.8% to an annual rate of 1.413 million.

Internet Computer (CRYPTO: INJ) turned out to be the biggest loser.

At the time of writing, the global crypto market cap rose to $1.28 trillion, recording a 24-hour gain of 2.1%. BTC was trading higher by 2.8% at $30,355 while ETH rose by around 1.5% to $2,112 on Tuesday.

Here are the top ten crypto gainers and losers over the past 24 hours:

Gainers

  • Internet Computer (CRYPTO: ICP)

Price: $6.89
24-hour gain: 12.9%

  • Arbitrum (CRYPTO: ARB)

Price: $1.77
24-hour gain: 10.2%

  • Oasis Network (CRYPTO: ROSE)

Price: $0.08032
24-hour gain: 9.6%

  • Zilliqa (CRYPTO: ZIL)

Price: $0.03399
24-hour gain: 8.5%

  • Synthetix (CRYPTO: SNX)

Price: $2.95
24-hour gain: 8.3%

Losers

  • Injective (CRYPTO: INJ)

Price: $9.08
24-hour drop: 2.6%

  • XDC Network (CRYPTO: XDC)

Price: $0.04387
24-hour drop: 2.4%

  • Rocket Pool (CRYPTO: RPL)

Price: $57.16
24-hour drop: 2%

  • Loopring (CRYPTO: LRC)

Price: $0.4081
24-hour drop: 1.9%

  • UNUS SED LEO (CRYPTO: LEO)

Price: $3.41
24-hour drop: 1.7%

Read This Next: Top 5 Industrials Stocks You May Want To Dump This Quarter

Total
0
Shares
Related Posts
Read More

Why Processa Pharmaceuticals Stock Is Soaring

Processa Pharmaceuticals shares are soaring Thursday after the company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine. Processa said the data obtained from the Phase 1b trial has been used to select two dosage regimens for the Phase 2 trial which will be in advanced or metastatic breast cancer given the FDA's agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.

PCSA